Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
Cocrystal Pharma, Inc. Announces Stock Symbol Change from BZNE to COCP
Marketwire - Wed Apr 16, 4:30PM CDT
Cocrystal Pharma, Inc. (the "Company"
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:25PM CDT
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Global Fracture Therapeutic Pipeline Review Report 2014
M2 - Tue Apr 15, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcn4c9/fracture) has announced the addition of the "Fracture - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Fracture - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Fracture - Companies Involved in Therapeutics Development - Eli Lilly and Company - Kuros Biosurgery AG - Novartis AG - Kolon Life Science, Inc. - TissueGene, Inc. - Radius Health, Inc. - Arcarios BV - Escape Therapeutics, Inc. - Orbsen Therapeutics Limited - OrgaNext Research BV Drug Profiles - teriparatide - BA-058 - KUR-113 - bimagrumab - (nandrolone decanoate cholecalciferol) - rusalatide acetate - KLS-Bfr - OsteoStem - TG-B - Stromal Cell Therapy For Fracture Repair - Bone Morphogenetic Protein Modulators - Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders For more information visit http://www.researchandmarkets.com/research/rcn4c9/fracture
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
Eli Lilly's $3 Billion Mistake
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
After a long court battle for Eli Lilly and partner Takeda, alleging that the companies didn't adequately disclose the cancer risks for Takeda's drug Actos, a jury verdict from the Federal Court of Louisiana came back with a harsher penalty than...
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Research and Markets: Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating
Business Wire - Mon Apr 14, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3stzbq/global_depression) has announced the addition of the "Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating" report to their offering.
Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating
M2 - Mon Apr 14, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh6tqs/global_depression) has announced the addition of the "Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating" report to their offering. Increasing public awareness regarding depression and associated disorders is expected to increase the acceptability of various drugs, and thereby an increase in drug penetration. For instance, ADAP educates high school students, teachers, and parents about depression disorder. ADAP aims to increase awareness about mood disorders in young people while stressing the need for evaluation and treatment. Similarly, the Peer-to-Peer Depression Awareness Campaign project is the student education component of the educational collaboration between the Depression Center and Ann Arbor public schools. The project aims to educate high school students about depression and depressive illnesses, and support them in finding creative ways to deliver this knowledge to their peers in order to reduce stigma, raise awareness, and help to promote the early detection of depression, bipolar disorder, and related illnesses. According to the report, one of the main drivers in this market is the increase in the number of patients suffering from depression. The increasing aging population is contributing to the growth of the market. The number of patients suffering from depression is increasing owing to increasingly elevated stress levels, unhealthy lifestyle, and social imbalances both in developing and developed nations. Further, the report states that one of the main challenges is the generic erosion of key blockbuster drugs. The introduction of low-priced generic drugs increases competition among vendors and reduces the cost of patented/branded drugs substantially. Key vendors dominating this space are - GlaxoSmithKline plc - Eli Lilly & Co. - Pfizer Inc - Forest Laboratories Inc. Other vendors mentioned in the report are - Astra Zeneca plc - Bristol Myers Squibb Co - Mallinckrodt Pharmaceuticals Inc. - Sanofi Aventis S.A. - Takeda Pharmaceutical Company Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Types - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Vendor Landscape - Key Vendor Analysis Visit http://www.researchandmarkets.com/research/gh...depression
Revera Board Appoints Thomas G. Wellner as President and Chief Executive Officer
CNW Group - Mon Apr 14, 9:05AM CDT
Revera Inc. is pleased to announce that its Board of Directors has appointed Thomas G. Wellner as President and Chief Executive Officer, effective immediately.
Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price...
Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin
PR Newswire - Mon Apr 14, 8:00AM CDT
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D).
American College of Endocrinology (ACE) focuses on emergency planning for people with diabetes at National Hurricane Conference
PR Newswire - Mon Apr 14, 8:00AM CDT
News Highlights:
Upgrade Alert for Eli Lilly (LLY)
Comtex SmarTrend(R) - Mon Apr 14, 7:07AM CDT
Eli Lilly (NYSE:LLY) was upgraded from Underperform to Hold at Jefferies today. The stock closed yesterday at $58.45 on volume of 5.4 million shares, above average daily volume of 4.9 million. In the past 52 weeks, Eli Lilly share prices have been bracketed by a low of $47.53 and a high of $60.46 and closed yesterday at $58.45, 23% above that low price. The 200-day and 50-day moving averages have moved 0.45% higher and 0.88% higher over the past week, respectively.
Acquisitions, Director Appointments, Collaborations, New Product Launches, and Earnings Guidance Revisions - Analyst Notes on Questcor, Regeneron, Lilly, Medtronic and Alexion
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
Verdict Gives Bladder Cancer Actos Users Reason for Action, According to Cancer Monthly
PRWeb - Sun Apr 13, 6:01AM CDT
The Japanese manufacturer of the diabetes drug Actos and its partner firm, Eli Lilly & Co., have been ordered to pay $9 billion to Terrence Allen, who was diagnosed with bladder cancer after taking Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064) The ruling was made April 8th in a federal court in Louisiana.